Current Report Filing (8-k)
April 14 2021 - 6:01AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
Date of Report (Date of earliest event reported): April
12, 2021
|
INMUNE BIO INC.
|
|
|
(Exact name of registrant as specified in charter)
|
|
Nevada
|
|
001-38793
|
|
47-5205835
|
(State or other jurisdiction
|
|
(Commission File Number)
|
|
(IRS Employer
|
of incorporation)
|
|
|
|
Identification No.)
|
1200 Prospect Street, Suite 525, La Jolla, CA
92037
(Address of Principal Executive Offices) (Zip Code)
(858) 964 3720
(Registrant’s Telephone Number, Including Area
Code)
Not Applicable
(Former Name or Former Address, If Changed Since Last
Report)
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of
the Act:
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered
|
Common Stock, par value $0.001 per shares
|
|
INMB
|
|
The NASDAQ Stock Market LLC
|
Indicate by check mark whether the registrant is an
emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mart
if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 1.02 Termination of a Material Definitive
Agreement.
As previously reported in a Current Report on
Form 8-K filed with the Securities and Exchange Commission on May 16, 2019, on May 15, 2019 INmune Bio Inc. (the “Company”)
entered into a purchase agreement (the “Agreement”) with Lincoln Park Capital Fund, LLC (“Lincoln Park”). Pursuant
to a letter dated April 12, 2021, the Company notified Lincoln Park that it was terminating the Agreement as permitted pursuant to the
terms of the Agreement.
SIGNATURES
Pursuant to the requirements of the Securities Exchange
Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
INMUNE BIO INC.
|
|
|
Date: April 13, 2021
|
By:
|
/s/ David Moss
|
|
|
David Moss
|
|
|
Chief Financial Officer
|
3
INmune Bio (NASDAQ:INMB)
Historical Stock Chart
From Jul 2024 to Aug 2024
INmune Bio (NASDAQ:INMB)
Historical Stock Chart
From Aug 2023 to Aug 2024